pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

COMPANY OVERVIEW

EngeneIC is a biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of chemotherapeutics and functional nucleic acids in cancer. The EDV™ is a first-in-class Cyto-Immunotherapy platform.

LOCATION

  • Lane Cove West, , Australia

  • New York, NY, USA

    • THERAPEUTIC AREAS

  • Oncology

    • WEBSITE

    https://engeneic.com/

    CAREER WEBSITE

    None

    SOCIAL MEDIA

    INVESTORS

    foley-ventures grt-capital-partners

    PRESS RELEASES


    Jun 28, 2022

    EnGeneIC’s second generation COVID-19 vaccine protects against all variants


    Nov 30, 2021

    Australian Biotech EnGeneIC Strikes Landmark Deal with Major US Biotech ImmunityBio for COVID-19 Vaccine and Cancer Treatment


    Jun 1, 2020

    EnGeneIC Announces Acceptance of Abstract to the Annual Meeting of the American Society of Clinical Oncology 2020


    Mar 16, 2020

    EnGeneIC Announces Publication in Cancer Cell of a Scientific Paper Highlighting the Ability of EDV™ Nanocells to Mount Dual Assault on Cancer Cells


    Feb 12, 2020

    EnGeneIC Novel Oncology-Focused Nanotechnology Featured in InsightsCare


    For More Press Releases
    Google Analytics Alternative